Physician profile
Kelly Welsh
NPI 1144663964
$1,405.54
in general payments reported to CMS, 2019-2025
19 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $341 · 2023: $498 · 2024: $400 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $360.52 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Daiichi Sankyo INC. | $190.95 | 2022-2025 | Injectafer |
| Exact Sciences Corporation | $120.74 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $95.89 | 2022-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $87.64 | 2023-2024 | Shingrix, Arexvy |
| Pfizer INC. | $81.79 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.19 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $61.98 | 2022-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Alexion Pharmaceuticals, INC. | $51.98 | 2022-2024 | Ultomiris |
| Sanofi Pasteur INC. | $45.63 | 2023-2025 | |
| Dynavax Technologies Corporation | $44.08 | 2022-2023 | Heplisav-B |
| Bausch Health US, LLC | $43.31 | 2024 | Wellbutrin |
| Xeris Pharmaceuticals, INC. | $32.29 | 2022-2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $24.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.81 | 2025 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $23.70 | 2024 | Inspire |
| Abbvie INC. | $16.86 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.76 | 2024 | Voquezna |
| Collegium Pharmaceutical, INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.